Comparison of LMA-Fastrach and I-gel for Blind Tracheal Intubation.

NCT ID: NCT01007370

Last Updated: 2017-08-03

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

160 participants

Study Classification

INTERVENTIONAL

Study Start Date

2010-03-31

Study Completion Date

2010-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The investigators aim to compare two different types of supraglottic devices for tracheal intubation in patients undergoing elective surgery under general anesthesia.

Our hypothesis is that the use of the I-gel supraglottic airway will result in a higher first attempt success rate of blind tracheal intubation.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Supraglottic airway devices such as LMA-Fastrach and I-gel provide patent airways during general anesthesia.

The LMA-Fastrach is designed to provide a conduit for blind or fiberoptically guided tracheal intubations. However, the success rate of tracheal intubation on the first attempt through this device varies between 50 and 87%.

The I-gel is a newer device for airway management which, with its wide bore, allows direct passage of a tracheal tube. Recent studies suggest that the I-gel is easy to insert and that limited experience is needed before a high success insertion rate is obtained.

In this prospective and randomized study, we will evaluate the performance of both devices for tracheal intubation in patients undergoing elective surgery under general anesthesia.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

General Anesthesia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

LMA-Fastrach

* Induction of general anesthesia with 1,5-2,5 mg/kg propofol and 1-3 mcg/kg fentanyl and neuromuscular relaxation with 0,6 mg/kg of rocuronium.
* Direct laryngoscopy, evaluation of laryngeal view grade according to Cormack-Lehane classification
* Insertion of LMA-Fastrach (sizes 3,4 or 5), establishment of ventilation
* Evaluation of glottic view through LMA-Fastrach using fibrescope (one out of ten patients)
* Tracheal intubation through the LMA-Fastrach
* With the endotracheal tube in place, the anaesthesiologist will proceed to the removal of supraglottic device

Group Type ACTIVE_COMPARATOR

Tracheal intubation

Intervention Type PROCEDURE

Tracheal intubation through a supraglottic airway device(LMA-Fastrach).

I-gel

* Induction of general anesthesia with 1,5-2,5 mg/kg propofol and 1-3 mcg/kg fentanyl and neuromuscular relaxation with 0,6 mg/kg of rocuronium.
* Direct laryngoscopy, evaluation of laryngeal view grade according to Cormack-Lehane classification
* Insertion of I-gel (sizes 3,4 or 5), establishment of ventilation
* Evaluation of glottic view through I-gel using fibrescope (one out of ten patients)
* Tracheal intubation through the I-gel
* With the endotracheal tube in place, the anaesthesiologist will proceed to the removal of supraglottic device

Group Type ACTIVE_COMPARATOR

Tracheal intubation

Intervention Type PROCEDURE

Tracheal intubation through a supraglottic airway device(I-gel).

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Tracheal intubation

Tracheal intubation through a supraglottic airway device(LMA-Fastrach).

Intervention Type PROCEDURE

Tracheal intubation

Tracheal intubation through a supraglottic airway device(I-gel).

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age 18 and older
* ASA physical status 1-3
* Patients undergoing elective surgery under general anesthesia, requiring endotracheal intubation

Exclusion Criteria

* ASA physical status 4-5
* Contraindications to muscle relaxation
* Anticipated or known difficult intubation or ventilation
* Patients with limited mouth opening (less than 2 cm)
* Patients at increased risk of aspiration, or having an history of symptomatic gastroesophageal reflux or hiatal hernia.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Centre hospitalier de l'Université de Montréal (CHUM)

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Nathalie Massicotte, MD, FRCPC

Role: PRINCIPAL_INVESTIGATOR

Centre hospitalier de l'Université de Montréal (CHUM)

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Centre Hospitalier de l'Université de Montréal-Hôpital Notre-Dame

Montreal, Quebec, Canada

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Canada

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

NM 2010-001

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.